TAKEDA PHARMACEUTICAL CO LTD (TAK)
U.S. FDA Accepts Takedas Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohns Disease
U.S. FDA Accepts Takedas Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohns Disease
📈 **POSITIVE** • Medium confidence analysis (78%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business